Cirrhosis Reshapes Immune Microenvironment, Limiting Hepatocellular Carcinoma Immunotherapy Efficacy
Key Insights
Cirrhosis fundamentally alters the hepatic immune microenvironment by reducing dendritic cell abundance, promoting T-cell exhaustion, and skewing macrophages toward immunosuppressive phenotypes, creating barriers to effective immunotherapy in hepatocellular carcinoma (search).
Immune checkpoint inhibitor monotherapy yields only 15-20% objective response rates in HCC patients, with combination treatments showing improved but still limited efficacy, particularly in cirrhotic patients.
Novel therapeutic strategies targeting cirrhosis-driven immune dysfunction include dendritic cell activation, metabolic reprogramming of T cells, macrophage repolarization, and neutrophil extracellular trap disruption to enhance immunotherapy responses.
Hepatocellular carcinoma (search) (HCC) represents a formidable clinical challenge, ranking as the sixth most prevalent cancer globally and the third leading cause of cancer-related deaths. Despite advances in immunotherapy, particularly immune checkpoint inhibitors, treatment outcomes remain suboptimal, with objective response rates of only 15-20% for monotherapy approaches. A comprehensive analysis reveals that cirrhosis, present in 80-90% of HCC cases, fundamentally reshapes the hepatic immune microenvironment, creating significant barriers to effective immunotherapy.
Cirrhosis-Driven Immune Dysfunction
The pathological features of liver cirrhosis (search) extend far beyond structural changes, profoundly altering immune cell populations and their functions. Research demonstrates that cirrhosis reduces dendritic cell (DC) abundance while constraining their maturation under immunoregulatory cues. Studies show that individuals with acute decompensated or stable cirrhosis exhibit fewer total DCs, a higher plasmacytoid/classical DC ratio, and elevated concentrations of interleukin-6 and IL-10 compared with healthy controls.
T-cell dysfunction emerges as a central feature of cirrhosis-associated immune suppression. Persistent inflammatory signals and metabolic imbalance extensively reprogram T-lymphocyte phenotypes, pushing CD8+ and CD4+ T-cell compartments toward chronic activation and eventual exhaustion. Peripheral blood from cirrhotic patients shows elevations in PD-1 (search), CTLA-4 (search), and TIM-3 (search) on CD8+ cells, with parallel loss of cytotoxic capacity and reduced interferon-γ secretion.
Metabolic Reprogramming and Immune Suppression
The metabolic landscape in cirrhosis creates additional barriers to effective immune responses. Heightened competition for glucose and amino acids, combined with disordered handling of lactate and fatty acids, exposes circulating and hepatic T cells to nutrient scarcity and metabolic stress. In liver tissue samples from cirrhotic patients, IDO protein expression is upregulated and accompanied by increased serum tryptophan metabolism to kynurenine, which activates the aryl hydrocarbon receptor and induces PD-1 (search) upregulation in CD8+ T cells.
Macrophage populations undergo significant reprogramming in cirrhosis, shifting from proinflammatory programs in early stages to immunoregulatory and tissue-reparative states as disease progresses. Single-cell studies in human cirrhotic liver have identified TREM2 (search)+CD9+ scar-associated macrophage populations that express abundant TGF-β (search) and promote collagen deposition while suppressing T-cell function.
Current Immunotherapy Limitations
The IMbrave150 phase 3 trial demonstrated that combining targeted therapy with immunotherapy extended median overall survival from 13.4 to 19.2 months in unresectable, advanced HCC. However, the IMbrave050 study revealed that recurrence during follow-up remained near 50% despite combined immunotherapy and targeted therapy in postoperative patients. These outcomes highlight the persistent challenges posed by the cirrhotic immune microenvironment.
Child-Pugh scoring remains the standard clinical tool for assessing liver function, with most randomized clinical trials requiring Child-Pugh Class A as an inclusion criterion. Recent meta-analysis of 699 Child-Pugh B patients demonstrated that some can achieve objective responses to immune checkpoint inhibitors, though they exhibit poorer overall survival and outcomes more readily constrained by baseline liver function.
Emerging Therapeutic Strategies
Dendritic Cell Targeting
Robust antitumor immunity in HCC depends strongly on the cDC1 lineage, noted for cross-presentation and licensing CD8+ T cells. Experimental work shows that inhibitory cues within the tumor bed, including VEGF (search) and IL-10, directly disrupt DC maturation and differentiation. Iron-manganese bimetal nanovaccines can provoke pyroptosis, releasing damage-associated signals that activate the cGAS-STING pathway, driving type I interferon production and DC maturation.
T-Cell Metabolic Restoration
Strengthening T-cell activity requires addressing both exhaustion programs and metabolic fitness. Enforced expression of PGC-1α increases mitochondrial biogenesis and improves CD8+ T-cell fitness. Short courses of IL-15, including engineered hyper-IL-15, can expand CD8+ effectors and boost their function, with antitumor activity reported in liver metastasis models.
Macrophage Reprogramming
Concurrent inhibition of CCR2 (search) and CCR5 (search) with agents such as cenicriviroc limits the influx of suppressive macrophages and promotes fibrotic regression in hepatic models. Blocking CSF1R (search) can lessen tumor-associated macrophage-driven immunosuppression and act synergistically with PD-1 (search) blockade. The interaction between CD47 (search) on tumor cells and SIRPα on phagocytes delivers an antiphagocytic signal, and interrupting this pathway enhances macrophage engulfment and improves cross-presentation.
Neutrophil Modulation
Neutrophil extracellular trap (NET) formation represents a key pathogenic output that facilitates immune escape. Pharmacologic dismantling with DNase I and inhibition of PAD4 using agents such as GSK484 reduce NET burden and enhance T-cell entry. Inhibition of CXCR2 (search) with AZD5069 combined with immune checkpoint inhibitor therapy expands antitumor neutrophil populations and lowers tumor burden in experimental HCC.
Circular RNA-Based Therapeutics
Circular RNAs (circRNAs) represent an emerging therapeutic platform for HCC treatment, offering unique advantages including high stability, low immunogenicity, and multiple functional capabilities. These synthetic circRNAs can be engineered for protein production, RNA and protein sequestration, or multifunctional roles.
Vaccine Applications
CircRNA vaccines have demonstrated promising preclinical results in HCC models. One group designed a circRNA neoantigen vaccine expressing a self-splicing intron encoding mutated PTPN2 (search), delivered via circRNA-lipid nanoparticle complexes. The vaccine significantly inhibited tumor growth in a dose-dependent manner in subcutaneous murine HCC models and demonstrated prophylactic effects.
Another approach involved a circRNA-based vaccine encoding GPC3 (search), highly expressed in HCC. The circGPC3 vaccine demonstrated sustained antigen production and, when combined with a TLR4 agonist adjuvant, effectively suppressed tumor progression in both subcutaneous and orthotopic tumor mouse models.
miRNA Sequestration Platforms
Synthetic circRNAs can function as miRNA sponges, sequestering oncogenic miRNAs to restore tumor suppressor function. A multifunctional circRNA platform, circSC25-αPD1, acts as a sponge for oncogenic miR-25 while expressing an anti-PD-1 (search) single-chain variable fragment. This engineered circRNA demonstrated strong tumor-suppressive effects in both cellular assays and mouse models, combining miRNA sequestration and protein translation functions in a single platform.
Clinical Considerations and Future Directions
When considering combination immunotherapy in cirrhotic HCC, several practical precautions are essential. Enhanced dynamic monitoring of liver function should be implemented, including parameters such as bilirubin, albumin, INR, and ascites management indicators. Child-Pugh B patients should routinely receive individualized risk-benefit evaluations and be preferentially considered for clinical trials.
Future research should emphasize models that more closely mirror human disease, including long-duration fibrosis across multiple causes and humanized mouse platforms. Clinical studies incorporating longitudinal sampling from tumor core and margin, together with integrated profiling of single-cell, spatial, and metabolomic layers, will facilitate reconstruction of cellular circuits and identification of early intervention nodes.
The development of pragmatic biomarkers deserves priority, including NET-related markers in plasma such as H3Cit-DNA and MPO-DNA, neutrophil subsets marked by PLAUR or CD10 with ALPL, and chemoattractants such as IL-8 and CXCL9 for stratification and prediction. Early-phase trials are needed to test combinations that pair immune cell-targeted agents with checkpoint inhibitor therapy.
Cirrhosis represents not merely a backdrop for HCC development but a central driver of immunotherapy outcomes. Only through mechanism-guided, patient-centered approaches that incorporate longitudinal sampling across disease progression, supported by rigorous preclinical validation and thoughtful integration of cirrhosis-related biomarkers, can the concept of relieving fibrosis-associated immunosuppression be translated into safe and effective clinical strategies for affected patients.